Results 61 to 70 of about 1,042,760 (299)

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

open access: yesMolecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson   +11 more
wiley   +1 more source

High-temperature creep behaviors of polybutene-1 with different chain microstructure and molecular weight

open access: yesPolymer Testing, 2023
The creep resistance of polymer determines the dimensional stability of product under stress. The isotactic polybutene-1 (iPB) with outstanding high-temperature creep resistance and stress-crack resistance is applied widely in the field of hot-water ...
Yuanjin Zhao   +3 more
doaj  

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

open access: yesMolecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma   +9 more
wiley   +1 more source

Kinetic study of HTPB (Hydroxyl Terminated Polybutadiene) Synthesis Using Infrared Spectroscopy

open access: yesIndonesian Journal of Chemistry, 2020
A kinetic study of HTPB synthesis by radical polymerization of butadiene with hydrogen peroxide initiator was conducted using infrared spectroscopy. HTPB conversion was determined based on the conjunction termination rate constant, and all polymerization
Heri Budi Wibowo   +3 more
doaj   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

open access: yesMolecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci   +6 more
wiley   +1 more source

Evolution of crosslinking networks structure and thermo-oxidative aging behavior of unfilled NR/BR blends with TBIR as extra functional compatibilizer

open access: yesPolymer Testing, 2022
As the most popular rubber blends in rubber industry, the aging behaviors of NR/BR vulcanizates have been a major challenge in science and industry. Our previous work reported the substitution of trans-1,4-poly (isoprene-co-butadiene) (TBIR) for BR in ...
Huafeng Shao, Qinrui Guo, Aihua He
doaj  

TRPM8 levels determine tumor vulnerability to channel agonists

open access: yesMolecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo   +18 more
wiley   +1 more source

Multi-heterostructure composites of Fe3O4 coated Janus nanoparticles and MWCNTs with high microwave absorption

open access: yesPolymer Testing, 2023
Microwave-absorbing materials with heterostructure represent a major challenge and opportunity in enabling strong microwave absorption over a wide bandwidth.
Hengqian Jin   +4 more
doaj  

Polymeric electrochromics

open access: yesChemical Communications, 2005
Conducting polymers are excellent candidates for applications in displays, mirrors, windows, light-emitting diodes, photovoltaics, near-infrared devices and electrochromic devices. From these potential applications, in this article, we will focus on the electrochromic polymers and devices.
openaire   +3 more sources

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

open access: yesMolecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy